




Metronidazole: Updating USP Methods

Application
Pharmaceutical
Robert Ricker

This pharmaceutical was one of the top 30 prescribed generic drugs in recent years and is used for antibacterial/antiprotozoal treatment. The USP 23 / NF 18 method requires an L7 column with a configuration of 150 x 4.6 mm. This application demonstrates the advantage of selecting a modern silica packing, ZORBAX Eclipse XDB-C8, as an L7 equivalent to the traditional ZORBAX C8 column choice.

Highlights

- For acidic compounds, improved tailing factors and overall peak shape are best achieved on the ZORBAX Eclipse XDB-C8.
- Higher efficiency is achieved with a significant increase in sensitivity (peak height) using ZORBAX Rapid Resolution columns.



Conditions:

A: ZORBAX C8 (4.6 x 150 mm, 5 μ m) (Agilent P/N: 883952-706)

B: Eclipse XDB-C8 (4.6 x 150 mm, 5 μ m) (Agilent P/N: 993967-906)

C: Eclipse XDB-C8 Rapid Resolution (4.6 x 150 mm, 3.5 μ m) (Agilent P/N: 963967-906)

Mobile Phase: 80:20, Water:Methanol

1 mL/min, Ambient, Detect. UV (254 nm)



Agilent Technologies

*Robert Ricker is an application chemist
based at Agilent Technologies, Wilmington,
Delaware.*

For more information on our products and
services, visit our website at:
www.agilent.com/chem

Copyright© 2002 Agilent Technologies, Inc.
All Rights Reserved. Reproduction,
adaptation or translation without prior
written permission is prohibited, except as
allowed under the copyright laws.

Agilent shall not be liable for errors
contained herein or for incidental or
consequential damages in connection with
the furnishing, performance, or use of this
material.

Information, descriptions, and specifications
in this publication are subject to change
without notice.

Printed in the USA
April 25, 2002
5988-6387EN



Agilent Technologies